News

Receiving the 510(k) enables I-Flow to start on the path to clinical studies on the dressing in keeping with a plan to make the product commercially available in

Health Canada and the FDA have approved the initiation of studies of CPI-613, which will be conducted at clinical trial sites in both the US and Canada. The

Under the terms of the agreement, Genzyme will gain access to elements of Asterion’s IP portfolio surrounding a specific protein target and will perform research work designed to

Affitech said that it has successfully used its molecule based antibody screening system that included its proprietary antibody library and high throughput screening technology to identify several fully

According to the company, Mr Kaiser brings more than three decades of executive-level leadership to the board at a time when RBC Life Sciences is focusing on aggressive

Mr Kilvington will be responsible for scientific and managerial leadership of the company’s microbiology activities in support of the discovery and development of new products for contact lens

Pursuant to the stock purchase agreement, Nerveda will fund DioGenix with at least $5 million to accelerate and expand the company’s proprietary programs, led by blood-based tests for

The Phase I trial was a randomized, double-blind, placebo-controlled, single ascending dose study in 26 healthy volunteers who received the medication or placebo subcutaneously. The objective of the

The new drug application (NDA) submission was supported by two Phase III clinical trials, involving more than 2,000 patients worldwide. The studies assessed the efficacy and safety of